Objectives: To examine the impact of a two-part special edition of the Australian Broadcasting Corporation's science journalism program Catalyst (titled Heart of the matter), aired in October 2013, that was critical of HMG-CoA reductase inhibitors (“statins”).
Design, setting and participants: Population-based interrupted time-series analysis of a 10% sample of Australian long-term concessional beneficiaries who were dispensed statins under the Pharmaceutical Benefits Scheme (about 51% of all people who were dispensed a statin between 1 July 2009 and 30 June 2014); dispensing of proton pump inhibitors (PPIs) was used as a comparator.
Main outcome measures: Change in weekly dispensings and discontinuation of use of statins and PPIs, adjusting for seasonal and long-term trends, overall and (for statins only) stratified by the use of cardiovascular and diabetes medicines.
Results: In our sample, 191 833 people were dispensed an average of 26 946 statins weekly. Following the Catalyst program, there was a 2.60% (95% CI, 1.40%–3.77%; P < 0.001) reduction in statin dispensing, equivalent to 14 005 fewer dispensings Australia-wide every week. Dispensing decreased by 6.03% (95% CI, 3.73%–8.28%; P < 0.001) for people not dispensed other cardiovascular and diabetes medicines and 1.94% (0.42%–3.45%; P = 0.01) for those dispensed diabetes medicines. In the week the Catalyst program aired, there was a 28.8% (95% CI, 15.4%–43.7%; P < 0.001) increase in discontinuation of statin use, which decayed by 9% per week. An estimated 28 784 additional Australians ceased statin treatment. Discontinuation occurred regardless of the use of other cardiovascular and diabetes medicines. There were no significant changes in PPI use after the Catalyst program.
Conclusions: Following airing of the Catalyst program, there was a temporary increase in discontinuation and a sustained decrease in overall statin dispensing. Up until 30 June 2014, there were 504 180 fewer dispensings of statins, and we estimate this to have affected 60 897 people.
- 1. Australian Broadcasting Corporation. Catalyst. Heart of the matter. Sydney: ABC, 2014. http://www.abc.net.au/catalyst/heartofthematter (accessed Apr 2015).
- 2. Australian Broadcasting Corporation. Media Watch. Catalyst challenges the mainstream. Sydney: ABC, 2013. http://www.abc.net.au/mediawatch/transcripts/s3888657.htm (accessed Jan 2015).
- 3. National Heart Foundation of Australia. The National Heart Foundation of Australia's summary of the recommendations for cholesterol management. Canberra: NHF, 2014. http://www.heartfoundation.org.au/SiteCollectionDocuments/Heart%20Foundation%20summary%20of%20recommendations%20for%20cholesterol%20management%20-%20Catalyst%20-%20FINAL.pdf (accessed Mar 2014).
- 4. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-2934.
- 5. Australian Government Department of Health. Australian Statistics on Medicines 2011. Canberra: Department of Health, 2013. http://www.pbs.gov.au/statistics/asm/2011/australian-statistics-on-medicines-2011.pdf (accessed Jul 2014).
- 6. Morgan TK, Williamson M, Pirotta M, et al. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012; 196: 50-53. https://www.mja.com.au/journal/2012/196/1/national-census-medicines-use-24-hour-snapshot-australians-aged-50-years-and. (accessed May 2014). <MJA full text>
- 7. National Heart Foundation of Australia. Cholesterol still important risk factor for heart disease. Sydney: NHF, 2013. http://www.abc.net.au/mediawatch/transcripts/1341_heartfoundation1.pdf (accessed Mar 2014)
- 8. National Heart Foundation of Australia. The impact of ‘ABC Catalyst' on lipid modifying medication use. Sydney: NHF, 2013. http://www.heartfoundation.org.au/news-media/Media-Releases-2013/Documents/The%20Impact%20of%20ABC%20Catalyst%20on%20Lipid%20Modifying%20Medication%20Use%20Survey%202013.pdf (accessed Dec 2014)
- 9. Australian Capital Territory Medicare Local. Statin use survey results. Canberra: ACTML, 2014. http://www.actml.com.au/Uploads/Documents/Statin%20use%20survey%20results_20140401115619.pdf (accessed Jan 2015).
- 10. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health 2000; 24: 603-606.
- 11. Box GEP, Jenkins GM, Reinsel GC. Time series analysis: forecasting and control. 4th ed. Hoboken, NJ: John Wiley, 2008.
- 12. Australian Government Department of Health. PBS and RPBS Section 85 Date of Processing and Date of Supply Data. Canberra: Department of Health, 2014. http://www.pbs.gov.au/info/statistics/dos-and-dop/dos-and-dop (accessed Jan 2015).
- 13. Corderoy A. “Miracle” drugs put thousands at risk. Sydney Morning Herald 2012; 1 Mar. http://www.smh.com.au/national/health/miracle-drugs-put-thousands-at-risk-20120229-1u3ia.html (accessed Nov 2014).
- 14. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
- 15. Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
- 16. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Sydney: National Stroke Foundation, 2012. http://strokefoundation.com.au/site/media/AbsoluteCVD_GL_webready.pdf (accessed Mar 2015).
- 17. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010; 192: 254-259. <MJA full text>
- 18. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821.
- 19. Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
- 20. Australian Broadcasting Corporation. Catalyst ‘Heart of the Matter' Investigation Report. Canberra: ABC, 2014. http://about.abc.net.au/wp-content/uploads/2014/05/Catalyst-Heart-of-the-Matter-ACA-Investigation-Report.pdf (accessed Dec 14).
- 21. Casula M, Tragni E, Catapano AL. Adherence to lipid-lowering treatment: the patient perspective. Patient Prefer Adherence 2012; 6: 805-814.
- 22. Sambrook PN, Chen JS, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 2010; 193: 154-156. <MJA full text>
- 23. Lagarde M. How to do (or not to do).. assessing the impact of a policy change with routine longitudinal data. Health Policy Plan 2012; 27: 76-83.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.